2017 PAINWeekEND - Jacksonville, FL

UAN 0530-0000-17-028-L04-P

AANP Rx Hours 0.0

Course Description

Chart documentation is important in any practice, but even more so when working with chronic pain patients. The treatment of chronic pain management comes with increased potential for litigation. There are important steps that prescribers must take with their documentation to lessen that risk. As a case reviewer and expert witness, I will highlight important areas that should be documented, as well as what safe guards to use when using electronic medical records. What is being looked at? What is vital to every chronic pain chart? What must be included in your charts if they are ever called into question?

UAN 0530-0000-17-034-L04-P

AANP Rx Hours 0.25

Course Description

Participants will learn the pathoetiology of central pain syndromes (CPS). Six specific CPS will be described and clinical aspects will be discussed: multiple sclerosis, Parkinson's disease, phantom limb pain, spinal cord injury, poststroke pain syndrome, and traumatic brain injury. Treatment of an individual CPS as well as the general problem of CPS will be discussed.

UAN 0530-0000-17-019-L04-P

AANP Rx Hours 1.0

Course Description

Nonopioid analgesics are oftentimes considered first-line therapy for most chronic pain syndromes. A strong understanding of these agents' mechanism of action, pharmacokinetics, and toxicity profiles is paramount for today's pain practitioner. This course will provide an in-depth look at each of the agents within these drug classes, their potential role in pain management, and available data supporting their use. Additionally, clinically relevant monitoring pearls will be discussed.

UAN 0530-0000-17-018-L04-P

AANP Rx Hours 0.20

Course Description

Opioid emergencies have risen with the increase in prescribing of opioids. It is imperative that prescribers of opioids know when to coprescribe naloxone therapy to their patients. It goes beyond the patient suspected of misuse and abuse. This presentation will focus on the patients you might not consider at risk for an opioid overdose.

UAN 0530-0000-17-016-L04-P

AANP Rx Hours 0.25

Course Description

During this course, we will go over the clinical symptomatology of migraine in a number of its various forms, as well as the pathophysiology of migraine. Also examined will be the acute as well as prophylactic treatment of migraine using evidence based criteria.

UAN 0530-0000-17-020-L04-P

AANP Rx Hours 1.0

Course Description

Designer drugs are structurally related to illegal psychoactive drugs and include cathinones (bath salts and flakka), synthetic cannabinoids (K2), piperazines (Molly), salvia, kratom, and desomorphine (krokodil). Often designer drugs are readily available on the Internet or in head shops and skirt regulation through the development of novel analogs and labeling the products "not for human consumption." These novel psychoactive substances are consumed typically by younger males via various routes and modes for their desirable effects; however, undesirable and even life-threatening reactions or death may occur. Additionally, designer drugs are often coingested with other psychoactive substances and may be metabolized through cytochrome P450 pathways leading to drug-drug interactions furthering the potential for harm. Management is normally with supportive measures and symptomatic care. Unfortunately, most of these agents are challenging to detect as they are not readily identified by immunoassay urine drug testing, though some may lead to false positives. More advanced testing with liquid or gas chromatography/mass spectroscopy is able to detect designer drugs but is limited due to its availability, cost, delay in results, and the ever-changing designer drug structures.